Metastasis free survival in older men with nonmetastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: An FDA-pooled analysis.
Harpreet Singh(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Anup Amatya(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Michael H. Brave(United States Food and Drug Administration), James Xu(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Jamie R. Brewer(Center for Democracy in the Americas), Marc R. Theoret(United States Food and Drug Administration), Mitchell S. Anscher, Sundeep Agrawal(Center for Drug Evaluation and Research), Elaine Chang(Center for Drug Evaluation and Research), Chana Weinstock(United States Food and Drug Administration), Yutao Gong(Center for Drug Evaluation and Research), Dow-Chung Chi(Center for Drug Evaluation and Research), Lijun Zhang(Dalian Medical University), M Hadadi(Center for Drug Evaluation and Research)
Cited by 0
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k